Dataset from A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007363
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab
SC) maintenance treatment on clinical remission at Week 52 in participants with moderately to
severely active ulcerative colitis (UC) who achieved clinical response following
administration of vedolizumab intravenous (vedolizumab IV) induction therapy.
创建时间：
2026-01-07
